LGVN
LGVN
NASDAQ · Biotechnology

Longeveron Inc-A

$0.51
+0.00 (+0.39%)
As of Feb 8, 2:28 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 3.62M 3.54M 3.93M
Net Income -89,087 -86,327 -108,943
EPS
Profit Margin -2.5% -2.4% -2.8%
Rev Growth +10.0% +8.8% +5.3%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 4.11M 4.00M 4.40M
Total Equity 6.10M 6.27M 5.45M
D/E Ratio 0.67 0.64 0.81
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -137,252 -134,724 -147,370
Free Cash Flow -56,767 -61,141 -91,187